{
  "nct_id": "NCT38662174",
  "indication": "Melanoma",
  "phase": "Phase 2",
  "sample_size": 225,
  "duration_weeks": 75,
  "dropout_rate": 0.27,
  "blinding": "double-blind",
  "control_arm": "placebo",
  "primary_endpoints": [
    "Objective response rate"
  ],
  "secondary_endpoints": [
    "Progression-free survival",
    "Overall survival"
  ],
  "outcome_summary": "Study terminated early due to futility",
  "success": 0,
  "failure_reason": "Dose selection suboptimal",
  "start_date": "2020-08-08",
  "completion_date": "2022-01-15"
}